Trimbow ([beclomethasone + formoterol + glycopyrrolate]; Chiesi Farmaceutici) is a fixed triple-combination product consisting of glycopyrrolate (a LAMA), formoterol (a LABA), and beclometasone (an ICS), used to relieve the symptoms of moderate to severe chronic obstructive pulmonary disease (COPD). Trimbow’s market potential will ultimately be limited by its restricted geographic scope, as it has only been developed for the European market. Although the drug was the first inhaled corticosteroid/long-acting beta 2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) to launch in the EU, GlaxoSmithKline’s Trelegy Ellipta ([fluticasone furoate + umeclidinium + vilanterol]) was approved just four months later, significantly reducing the impact of Trimbow’s first-to-market status. Further competition will likely come from AstraZeneca’s PT010 ([budesonide + glycopyrrolate + formoterol]), which is expected to launch in the European markets from Q1 2021. Datamonitor Healthcare believes Chiesi Farmaceutici will not seek regulatory approval in the US or Japan, meaning Trimbow will remain limited to the European market.
LIST OF FIGURES
10 Figure 55: Tudorza Pressair sales for COPD across the US, Japan, and major EU markets, by country, 2017–26
12 Figure 67: Datamonitor Healthcare’s drug assessment summary of Ultibro/Utibron for COPD
14 Figure 68: Datamonitor Healthcare’s drug assessment summary of Ultibro/Utibron for COPD
LIST OF TABLES 5 Table 1: Trimbow drug profile
7 Table 2: Trimbow Phase III data in COPD
9 Table 3: Trimbow Phase III trial in COPD
15 Table 4: Trimbow sales for COPD across the five major EU markets, by country ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.